The company's principal activity is the development of biopharmaceutical products based on its patented gene delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of its gene delivery technology include gene therapies for cancer, dna vaccines for infectious diseases or cancer, and dna therapeutic protein delivery. The company has retained all rights to its internally developed cancer product candidates. In addition, it collaborates with major pharmaceutical and biotechnology companies that give access to complementary technologies or greater resources. These strategic partnerships provide mutually beneficial opportunities to expand the company's product pipeline and serve significant unmet medical needs.
